References
- Rowley, J. (1973) "A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining", Nature 43, 290–293.
- Daley, G.Q., Van Erten, R.A. and Baltimore, D. (1990) "Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gen of the Philadelphia chromosome", Science 247, 824–830.
- Goldman, J., Szycllo, R., Horowitz, M.M., Gale, R.P., Ash, R.C., Atkinson, K., Dicke, K.A., Gluckman, E., Herzig, R.H. and Marmont, A. (1993) "Choice of pretransplant treatment and timing of transplant for chronic myelogenous leukemia in chronic phase", Blood 82, 2235–2238.
- Druker, B., Talpaz, M., Resta, D., Bin Peng, RN., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H., Capdeville, R., Ohno-Jones, S. and Sawyers, C. (2001) "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", N. Engl. J. Med. 344, 1031–1037.
- Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoeliner, U., Talpaz, M. and Drucker, B. (2002) "Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia", N. Engl. J. Med. 346, 645–652.
- Kitiyakara, C. and Atichartakarn, V. (2002) "Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, 5TI571", NDT 17, 685–687.
- Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, GM., Fanning, S., Zimmermann, J. and Lydon, N.B. (1996) "Effects of selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells", Nat. Med. 2, 561–566.
- Gilbert, R.E., Kelly, D.J., McKay, T., Chadban, S., Hill, P.A., Cooper, ME., Atkins, R.C. and Nikolic-Paterson, D.J. (2001) "PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis", Kidney Int. 59, 1324–1332.